191 related articles for article (PubMed ID: 17762923)
21. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.
Zhao KH; Hernandez DJ; Han M; Humphreys EB; Mangold LA; Partin AW
Urology; 2008 Aug; 72(2):396-400. PubMed ID: 18372031
[TBL] [Abstract][Full Text] [Related]
22. [Prognosis and predictive factors in prostate cancer].
Albiges-Sauvin L; Lévy A; Massard C; Fizazi K
Bull Cancer; 2009 Apr; 96(4):439-49. PubMed ID: 19357018
[TBL] [Abstract][Full Text] [Related]
23. Laparoscopic pelvic lymph-node dissection in prostate cancer before external beam radiotherapy: Risk factors of nodal involvement and relapse following intended curative treatment.
Bjerggaard Jensen J; Johansen JK; Graversen PH
Scand J Urol Nephrol; 2009; 43(1):19-24. PubMed ID: 18752151
[TBL] [Abstract][Full Text] [Related]
24. Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3375-3381. PubMed ID: 30583343
[TBL] [Abstract][Full Text] [Related]
25. Contemporary evaluation of the D'amico risk classification of prostate cancer.
Hernandez DJ; Nielsen ME; Han M; Partin AW
Urology; 2007 Nov; 70(5):931-5. PubMed ID: 18068450
[TBL] [Abstract][Full Text] [Related]
26. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
Nanda A; Chen MH; Renshaw AA; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
[TBL] [Abstract][Full Text] [Related]
27. Risk stratification in clinically localized prostate cancer.
Aprikian AG
Can J Urol; 2002 Jun; 9 Suppl 1():18-20. PubMed ID: 12121590
[TBL] [Abstract][Full Text] [Related]
28. An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk.
Williams SG; Duchesne GM; Gogna NK; Millar JL; Pickles T; Pratt GR; Turner S
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):351-7. PubMed ID: 16530339
[TBL] [Abstract][Full Text] [Related]
29. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases.
Osunkoya AO; Nielsen ME; Epstein JI
Am J Surg Pathol; 2008 Mar; 32(3):468-72. PubMed ID: 18300802
[TBL] [Abstract][Full Text] [Related]
30. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
Arcangeli G; Strigari L; Arcangeli S; Petrongari MG; Saracino B; Gomellini S; Papalia R; Simone G; De Carli P; Gallucci M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):975-82. PubMed ID: 19395188
[TBL] [Abstract][Full Text] [Related]
31. Validation of the Prostate Cancer Risk Index (PRIX): a simple scoring system to predict risk of biochemical relapse after radical prostatectomy for prostate cancer.
Yoshida T; Nakayama M; Matsuzaki K; Kobayashi Y; Takeda K; Arai Y; Kakimoto K; Nishimura K
Jpn J Clin Oncol; 2011 Nov; 41(11):1271-6. PubMed ID: 21971422
[TBL] [Abstract][Full Text] [Related]
32. Machine learning for improved pathological staging of prostate cancer: a performance comparison on a range of classifiers.
Regnier-Coudert O; McCall J; Lothian R; Lam T; McClinton S; N'dow J
Artif Intell Med; 2012 May; 55(1):25-35. PubMed ID: 22206941
[TBL] [Abstract][Full Text] [Related]
33. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
34. [Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer--a multi-institutional update].
Graefen M
Aktuelle Urol; 2004 Sep; 35(5):377-8. PubMed ID: 15384003
[No Abstract] [Full Text] [Related]
35. The newer the better? Comparison of the 1997 and 2001 partin tables for pathologic stage prediction of prostate cancer in China.
Gao X; Ren S; Lu X; Xu C; Sun Y
Urology; 2008 Nov; 72(5):1096-101. PubMed ID: 18822453
[TBL] [Abstract][Full Text] [Related]
36. The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes.
Taplin ME; Kantoff PW
J Clin Oncol; 2003 Oct; 21(19):3552-3. PubMed ID: 12913104
[No Abstract] [Full Text] [Related]
37. Predictive models and prostate cancer.
Karakiewicz PI; Hutterer GC
Nat Clin Pract Urol; 2008 Feb; 5(2):82-92. PubMed ID: 18259186
[TBL] [Abstract][Full Text] [Related]
38. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?
Choo R; Danjoux C; Morton G; Szumacher E; Sugar L; Gardner S; Kim M; Choo CM; Klotz L
Prostate; 2007 Nov; 67(15):1614-20. PubMed ID: 17823923
[TBL] [Abstract][Full Text] [Related]
39. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.
Eifler JB; Feng Z; Lin BM; Partin MT; Humphreys EB; Han M; Epstein JI; Walsh PC; Trock BJ; Partin AW
BJU Int; 2013 Jan; 111(1):22-9. PubMed ID: 22834909
[TBL] [Abstract][Full Text] [Related]
40. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
